In 2021, our group assessed the therapeutic efficacy of single and combination therapies using an AAV1 encoding human SERCA2a or BMPR2 and a STAT3 inhibitor named HJC0152 in a rat model of severe PAH induced by unilateral left pneumonectomy combined with a single injection of monocrotaline (PNT/MCT) [95,103]. This evidence concerns the gene BMPR2 and pulmonary arterial hypertension.